NCRI 2018 | Current treatment landscape of triple negative breast cancer
In this video, Adrian Harris, MD, DPhil, from the University of Oxford, Oxford, UK, compares the roles of platinum-based drugs and taxanes in triple negative breast cancer (TNBC), before discussing the intriguing progression-free survival and overall survival results from a recent study that compared PD-L1 blocking drugs with taxanes. The results are from an early trial and Prof. Harris hopes they will lead to further studies to potentially identify the expression of PD-L1 as a classifier for targeted therapy. This video was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.
Get great new content delivered to your inboxSign up